Feed consumption and weight gaining behavior of zucker fatty (fa/fa) rats with single and in combination treatment of clonidine and metformin

Ranjitsinh M. Rajput

Abstract


Background: Diabetes is metabolic disorder with high blood glucose level. Type-2 diabetes is associated with obesity, insulin resistance, and chronic hyperglycemia. So agents that are efficiently reduces weight gain along with diabetic control may play beneficial role in obese diabetic subjects.

Methods: Zucker Fatty Rats were used for the study. Animals were divided in four groups, (control group, Clonidine group, metformin group and combination group).  Normal weight gain and feed consumption data were obtained up to 9 weeks of age there after animals were started treatment according to above mentioned groups. During treatment again feed consumption and weight gain data were generated. The experimental results are expressed as the Mean ± SEM in each group. Statistical analysis has been performed by one way analysis of variance (ANOVA).

Results: The data suggest that there is decrease in body weight gain during the treatment with clonidine and in combination of clonidine and metformin. If we consider weight gain of control as 100 % weekly than clonidine group shows 10.45 % weight gain while metformin shows 96.5 % weight gain and in combination group it shows 33.63 % weight gain. So, there is significant reduction in weight gain of the group treated with clonidine and combination of clonidine and metformin. Same time there is reduction in feed consumption of animals.

Conclusions: The centrally acting drug Clonidine affects the feed consuming behavior and weight gain of animals. It shows hypophagic effect and reduces weight gain in single as well as in combination with metformin.


Keywords


Zucker fatty rats, body weight, feed consumption

Full Text:

PDF

References


Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007 Mar;125(3):217-30.

Dipiro JT, Talbert RL, Yees GC, Matake GR, Wells BG, Posey LM. Pharmacotherapy A pathophysiologic approach, 6th Edn; McGraw-Hill Medical publishing Division, 2005, 185-217, 1333-1367.

Satia MC, Damani RR, Goyal RK. Beneficial Effects of Clonidine in Streptozotocin-induced Diabetes and DOCA-hypertensive Rats. J Pharm Pharmacol 1997 Oct;49(10):1030-5.

Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ. Clonidine Prevents Insulin Resistance and Hypertension In Obese Dogs. Hypertension 1999 Jan;33(1 Pt 2):548-53.

Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW. Melmon and Morrelli’s Clinical pharmacology, 4th Edn. McGraw-Hill, 2000, 530-552.

Vigneri R, Goldfine ID. Role of Metformin in Treatment of Diabetes Mellitus. Diabetes Care 1987 Jan-Feb;10(1):118-22.

Charles River. Accelerating drug development, exactly. November 2011. Available at http://www.criver.com/sitecollectiondocuments/zucker%20fatty.pdf. Accessed 29 July 2012.

El-Mas MM, Abdel-Rahman AA. Intermittent clonidine regimen abolishes tolerance to its antihypertensive effect: a spectral study. J Cardiovasc Pharmacol 2007 Mar;49(3):174-81.

El-Mas MM, Abdel-Rahman AA. Reduced cardiac contractile force due to sympathovagal dysfunction mediates the additive hypotensive effects of limited-access regimens of ethanol and clonidine in spontaneously hypertensive rats. J Pharmacol Exp Ther 2010 Dec;335(3):852-60.

Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 2006 Jul 21;12(27):4369-76.